P Vincent Jenkins1, Annette Bowyer2, Clive Burgess3, Elaine Gray4, Steve Kitchen2, Paul Murphy5, Sean Platton6, Anne Riddell7, Pratima Chowdary7, Will Lester8. 1. Haemostasis and Thrombosis, Haematology Department, University Hospital of Wales, Cardiff, UK. 2. Department of Coagulation, Royal Hallamshire Hospital, Sheffield, UK. 3. Coagulation Laboratory, Great Ormond Street Hospital for Children NHS Trust, London, UK. 4. Haemostasis Section, National Institute for Biological Standards and Control, Potters Bar, UK. 5. Department of Haematology, Newcastle Upon Tyne Hospitals Newcastle upon Tyne, Newcastle upon Tyne, UK. 6. The Royal London Hospital Haemophilia Centre, Royal London Hospital, London, UK. 7. Katharine Dormandy Haemophilia Centre, Royal Free Hospital, London, UK. 8. Haemophilia Unit, University Hospitals Birmingham, Birmingham, UK.
Abstract
INTRODUCTION: The factor VIII mimetic emicizumab (Hemlibra, Hoffman-la Roche, Basel, Switzerland) has a novel mode of action that affects the laboratory monitoring of patients receiving this treatment. AIM: This guideline from the United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO) aims to provide advice for clinical and laboratory staff on appropriate use of laboratory assays in patients with Haemophilia A treated with emicizumab. METHODOLOGY: The guideline was prepared by a review of the available literature and discussion and revision by the authors. RESULTS: The guideline describes the effect of emicizumab on commonly used coagulations tests and provides recommendations on the use of assays for measurement of factor VIII and factor VIII inhibitor in the presence of emicizumab. The guideline also provides recommendations on measurement of emicizumab. CONCLUSION: Knowledge of the effect of emicizumab on coagulation tests and factor assays is required to ensure appropriate testing and monitoring of therapy in patients receiving this drug.
INTRODUCTION: The factor VIII mimetic emicizumab (Hemlibra, Hoffman-la Roche, Basel, Switzerland) has a novel mode of action that affects the laboratory monitoring of patients receiving this treatment. AIM: This guideline from the United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO) aims to provide advice for clinical and laboratory staff on appropriate use of laboratory assays in patients with Haemophilia A treated with emicizumab. METHODOLOGY: The guideline was prepared by a review of the available literature and discussion and revision by the authors. RESULTS: The guideline describes the effect of emicizumab on commonly used coagulations tests and provides recommendations on the use of assays for measurement of factor VIII and factor VIII inhibitor in the presence of emicizumab. The guideline also provides recommendations on measurement of emicizumab. CONCLUSION: Knowledge of the effect of emicizumab on coagulation tests and factor assays is required to ensure appropriate testing and monitoring of therapy in patients receiving this drug.
Authors: Anouk A M T Donners; László Gerencsér; Kim C M van der Elst; Toine C G Egberts; Moniek P M de Maat; Albert Huisman; Rolf T Urbanus; Mohsin El Amrani Journal: Res Pract Thromb Haemost Date: 2022-06-08
Authors: C Hermans; P L F Giangrande; B O'Mahony; P de Kleijn; M Bedford; A Batorova; J Blatný; K Jansone Journal: Orphanet J Rare Dis Date: 2020-08-24 Impact factor: 4.123